Neha Krishnamohan has served as a member of our Board of Directors since September 2022. Ms. Krishnamohan is currently the Chief Financial Officer and Chief Business Officer at Latigo Biotherapeutics, a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source. Previously, Ms. Krishnamohan was the Chief Financial Officer and Executive Vice President, Corporate Development at Artiva Biotherapeutics, Inc., an off-the-shell NK cell therapy company focused on autoimmune and oncology indications from April 2024 to December 2025. Ms. Krishnamohan served as Chief Financial Officer and Executive Vice President, Corporate Development at Kinnate Biopharma Inc., a publicly traded biopharmaceutical company from June 2021 until its acquisition by XOMA Corporation in April 2024. Prior to joining Kinnate, Ms. Krishnamohan was with Goldman Sachs where she held various roles since July 2008, most recently as Vice President in the Healthcare Investment Banking Group. During Ms. Krishnamohan s tenure at Goldman Sachs, she advised a variety of biopharmaceutical company Board of Directors and management teams on a broad range of strategic financial matters, and executing financings and leading M&A transactions. Ms. Krishnamohan holds a B.S.E. with a double major in Biomedical Engineering and Economics from Duke University. We believe that Ms. Krishnamohan is qualified to serve on our Board of Directors because of her business and financial expertise, including capital markets, and her experience as a senior executive in the biopharmaceutical industry.